Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01463709
Other study ID # 2011-049
Secondary ID
Status Completed
Phase Phase 1
First received October 26, 2011
Last updated February 19, 2013
Start date October 2011
Est. completion date June 2012

Study information

Verified date February 2013
Source Children's Hospital & Research Center Oakland
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Human Basal Cell Carcinomas (BCCs) can be ablated by treating them with nanosecond pulsed electric fields (nsPEF)


Description:

The purpose of this study is to determine if low energy, non-thermal, 100 ns pulses can ablate BCCs. The investigators consider this a non-significant risk study because our PulseCure system only applies 0.4 watts to the skin compared to the 40 watts applied by the currently used electrosurgical unit to remove skin lesions, the Hyfrecator. Since the PulseCure applies 1/100 of the energy and does not even heat the skin significantly, it represents a non-significant risk to the patient. Our study will provide the first data on the response of BCCs to these 100 ns pulses. The investigators will first treat three BCCs on BCNS patients with different pulse numbers to determine the pulse number needed to ablate. Once the investigators have the optimal pulse number, the investigators will use it to treat 20 normal patients with sporadic BCCs on their trunks. This should provide sufficient data to conclude whether or not nsPEF can ablate BCCs on normal individuals.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Study subjects must have had diagnosed at least one BCCon their trunk

2. The subject is from 18-75 years of age, inclusive.

3. The subject must sign and date all informed consent statements.

Exclusion Criteria:

1. The subject is exhibiting signs of a bacterial or viral infection, including fever.

2. The subject is unwilling to allow a biopsy of a malignant lesion for histological analysis.

3. The subject has a pace maker or other electronic device implanted

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
PulseCure pulse generator and Derm-pulse electrode
PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes. NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure

Locations

Country Name City State
United States Children's Hospital Research Center Oakland Oakland California

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital & Research Center Oakland

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Demonstrate the safety of PulseCure pulse generator and NanoBlate electrode and identify the optimal pulse number for treating basal cell carcinomas. 1. Conduct a non-significant risk feasibility clinical trial treating BCCs on the trunk of up to 9 Basal Cell Nevus Syndrome patients with BioElectroMed's PulseCure pulse generator and Derm-Pulse electrode to both demonstrate the safety of nsPEF therapy and identify the optimal pulse number for ablating BCCs. One year Yes
Secondary Determine the efficacy of the PulseCure pulse generator using the optimal pulse number. 2. Conduct a non-significant risk Pilot Clinical Trial treating BCCs on the trunk of 20 patients with sporadic BCCs using the optimal pulse number determined from the feasibility trial to assess the efficacy of this technique. one year No
See also
  Status Clinical Trial Phase
Completed NCT02828111 - Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Phase 2
Recruiting NCT01349361 - Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Phase 2
Recruiting NCT04389112 - Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions N/A
Terminated NCT02067104 - Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention Phase 2